Immunome (IMNM) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunome (IMNM) has outperformed Vericel (VCEL) over the past year, gaining 37.8% versus a gain of 17.3%. Over five years, IMNM leads with a +9.7% price change compared with -21.1% for VCEL. Immunome is the larger company by market cap ($2.28 billion vs $2.05 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | VCEL |
|---|---|---|
| Share price | $19.31 | $40.05 |
| Market cap | $2.28B | $2.05B |
| 1-day change | +1.13% | -1.69% |
| YTD return | -10.10% | +11.22% |
| 1-year return | +37.83% | +17.35% |
| 5-year return | +9.65% | -21.15% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | — | 47.34 |
| EPS (TTM) | $-2.52 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.06 | $49.32 |
| 52-week low | $13.49 | $28.95 |
| Distance from 52-week high | -35.76% | -18.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +82.29% | +51.24% |
| Average volume | 1.20M | 502.23K |
| Shares outstanding | 118.00M | 51.21M |
| Employees | 247 | 398 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed VCEL by 20.5 percentage points over the past year.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Healthcare · Biotechnology · 247 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Healthcare · Biotechnology · 398 employees
IMNM vs VCEL FAQ
Which is bigger, Immunome or Vericel?
Immunome (IMNM) is larger, with a market capitalization of $2.28B compared with $2.05B for Vericel (VCEL).
Which stock has performed better over the past year, IMNM or VCEL?
IMNM returned +37.83% over the past 12 months, compared with +17.35% for VCEL (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Vericel in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.